AR041459A1 - Derivados de indazolcarboxamidas su preparacion y su utilizacion en terapeutica - Google Patents
Derivados de indazolcarboxamidas su preparacion y su utilizacion en terapeuticaInfo
- Publication number
- AR041459A1 AR041459A1 ARP030103581A ARP030103581A AR041459A1 AR 041459 A1 AR041459 A1 AR 041459A1 AR P030103581 A ARP030103581 A AR P030103581A AR P030103581 A ARP030103581 A AR P030103581A AR 041459 A1 AR041459 A1 AR 041459A1
- Authority
- AR
- Argentina
- Prior art keywords
- indazol
- carboxamide
- nhr2
- optionally substituted
- alkyl
- Prior art date
Links
- 239000003814 drug Substances 0.000 title 1
- -1 phenoxy, morpholinyl Chemical group 0.000 abstract 7
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 5
- 101100294102 Caenorhabditis elegans nhr-2 gene Proteins 0.000 abstract 5
- 125000001072 heteroaryl group Chemical group 0.000 abstract 5
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 4
- 125000005843 halogen group Chemical group 0.000 abstract 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 4
- 125000001424 substituent group Chemical group 0.000 abstract 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 3
- 229910006074 SO2NH2 Inorganic materials 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 abstract 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 abstract 2
- 125000000565 sulfonamide group Chemical group 0.000 abstract 2
- 125000004001 thioalkyl group Chemical group 0.000 abstract 2
- XXJGBENTLXFVFI-UHFFFAOYSA-N 1-amino-methylene Chemical compound N[CH2] XXJGBENTLXFVFI-UHFFFAOYSA-N 0.000 abstract 1
- 125000004864 4-thiomethylphenyl group Chemical group 0.000 abstract 1
- 108091007914 CDKs Proteins 0.000 abstract 1
- 102000003903 Cyclin-dependent kinases Human genes 0.000 abstract 1
- 108090000266 Cyclin-dependent kinases Proteins 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- GUUKEBMLJNBQFY-UHFFFAOYSA-N n-(2,4-dichlorophenyl)-1h-indazole-3-carboxamide Chemical compound ClC1=CC(Cl)=CC=C1NC(=O)C1=NNC2=CC=CC=C12 GUUKEBMLJNBQFY-UHFFFAOYSA-N 0.000 abstract 1
- TVHZMCPIRRYVDT-UHFFFAOYSA-N n-(2-methoxyphenyl)-1h-indazole-3-carboxamide Chemical compound COC1=CC=CC=C1NC(=O)C1=NNC2=CC=CC=C12 TVHZMCPIRRYVDT-UHFFFAOYSA-N 0.000 abstract 1
- SQQNUPPSLLPUNH-UHFFFAOYSA-N n-(2-methylphenyl)-1h-indazole-3-carboxamide Chemical compound CC1=CC=CC=C1NC(=O)C1=NNC2=CC=CC=C12 SQQNUPPSLLPUNH-UHFFFAOYSA-N 0.000 abstract 1
- POGXZPJWXLBSNI-UHFFFAOYSA-N n-(2-phenylethyl)-1h-indazole-3-carboxamide Chemical compound N=1NC2=CC=CC=C2C=1C(=O)NCCC1=CC=CC=C1 POGXZPJWXLBSNI-UHFFFAOYSA-N 0.000 abstract 1
- XGGBTJFQPDBIIS-UHFFFAOYSA-N n-(3,4-dichlorophenyl)-1h-indazole-3-carboxamide Chemical compound C1=C(Cl)C(Cl)=CC=C1NC(=O)C1=NNC2=CC=CC=C12 XGGBTJFQPDBIIS-UHFFFAOYSA-N 0.000 abstract 1
- OKAGMYQPEOEZOK-UHFFFAOYSA-N n-(3-chlorophenyl)-1h-indazole-3-carboxamide Chemical compound ClC1=CC=CC(NC(=O)C=2C3=CC=CC=C3NN=2)=C1 OKAGMYQPEOEZOK-UHFFFAOYSA-N 0.000 abstract 1
- MCCGUNATWZOMTD-UHFFFAOYSA-N n-(3-pyridin-2-ylpropyl)-1h-indazole-3-carboxamide Chemical compound N=1NC2=CC=CC=C2C=1C(=O)NCCCC1=CC=CC=N1 MCCGUNATWZOMTD-UHFFFAOYSA-N 0.000 abstract 1
- GUIORGRGVNLBKU-UHFFFAOYSA-N n-(4-chlorophenyl)-1h-indazole-3-carboxamide Chemical compound C1=CC(Cl)=CC=C1NC(=O)C1=NNC2=CC=CC=C12 GUIORGRGVNLBKU-UHFFFAOYSA-N 0.000 abstract 1
- QXHYWPVNYRELDC-UHFFFAOYSA-N n-(4-methoxyphenyl)-1h-indazole-3-carboxamide Chemical compound C1=CC(OC)=CC=C1NC(=O)C1=NNC2=CC=CC=C12 QXHYWPVNYRELDC-UHFFFAOYSA-N 0.000 abstract 1
- MCPGTFMPDWURDA-UHFFFAOYSA-N n-(pyridin-2-ylmethyl)-1h-indazole-3-carboxamide Chemical compound N=1NC2=CC=CC=C2C=1C(=O)NCC1=CC=CC=N1 MCPGTFMPDWURDA-UHFFFAOYSA-N 0.000 abstract 1
- QQCNPBKSJANZPJ-UHFFFAOYSA-N n-(pyridin-3-ylmethyl)-1h-indazole-3-carboxamide Chemical compound N=1NC2=CC=CC=C2C=1C(=O)NCC1=CC=CN=C1 QQCNPBKSJANZPJ-UHFFFAOYSA-N 0.000 abstract 1
- GZZDBVORCJPXBJ-UHFFFAOYSA-N n-(pyridin-4-ylmethyl)-1h-indazole-3-carboxamide Chemical compound N=1NC2=CC=CC=C2C=1C(=O)NCC1=CC=NC=C1 GZZDBVORCJPXBJ-UHFFFAOYSA-N 0.000 abstract 1
- BPOADZNATAFUFP-UHFFFAOYSA-N n-[(2-chlorophenyl)methyl]-1h-indazole-3-carboxamide Chemical compound ClC1=CC=CC=C1CNC(=O)C1=NNC2=CC=CC=C12 BPOADZNATAFUFP-UHFFFAOYSA-N 0.000 abstract 1
- VDQVUXZQLQVTFP-UHFFFAOYSA-N n-[(4-methylphenyl)methyl]-1h-indazole-3-carboxamide Chemical compound C1=CC(C)=CC=C1CNC(=O)C1=NNC2=CC=CC=C12 VDQVUXZQLQVTFP-UHFFFAOYSA-N 0.000 abstract 1
- UPARAHPZQJZHMB-UHFFFAOYSA-N n-[2-(3,4-dimethoxyphenyl)ethyl]-1h-indazole-3-carboxamide Chemical compound C1=C(OC)C(OC)=CC=C1CCNC(=O)C1=NNC2=CC=CC=C12 UPARAHPZQJZHMB-UHFFFAOYSA-N 0.000 abstract 1
- BMJAFUGCPSXEBZ-UHFFFAOYSA-N n-[3-(2,6-dimethylphenyl)propyl]-5-nitro-1h-indazole-3-carboxamide Chemical compound CC1=CC=CC(C)=C1CCCNC(=O)C1=NNC2=CC=C([N+]([O-])=O)C=C12 BMJAFUGCPSXEBZ-UHFFFAOYSA-N 0.000 abstract 1
- DRHKBMTWDVYDPG-UHFFFAOYSA-N n-benzyl-1h-indazole-3-carboxamide Chemical compound N=1NC2=CC=CC=C2C=1C(=O)NCC1=CC=CC=C1 DRHKBMTWDVYDPG-UHFFFAOYSA-N 0.000 abstract 1
- XQJXNILPLUCHQG-UHFFFAOYSA-N n-phenyl-1h-indazole-3-carboxamide Chemical compound N=1NC2=CC=CC=C2C=1C(=O)NC1=CC=CC=C1 XQJXNILPLUCHQG-UHFFFAOYSA-N 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0212188A FR2845382A1 (fr) | 2002-10-02 | 2002-10-02 | Derives d'indazolecarboxamides, leur preparation et leur utilisation en therapeutique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR041459A1 true AR041459A1 (es) | 2005-05-18 |
Family
ID=32011336
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030103581A AR041459A1 (es) | 2002-10-02 | 2003-10-01 | Derivados de indazolcarboxamidas su preparacion y su utilizacion en terapeutica |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7482342B2 (https=) |
| EP (1) | EP1549620A1 (https=) |
| JP (1) | JP4762543B2 (https=) |
| AR (1) | AR041459A1 (https=) |
| AU (1) | AU2003299125A1 (https=) |
| FR (1) | FR2845382A1 (https=) |
| TW (1) | TWI331603B (https=) |
| WO (1) | WO2004031158A1 (https=) |
Families Citing this family (100)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005014554A1 (en) * | 2003-08-08 | 2005-02-17 | Astex Therapeutics Limited | 1h-indazole-3-carboxamide compounds as mapkap kinase modulators |
| FR2867778B1 (fr) * | 2004-03-16 | 2006-06-09 | Sanofi Synthelabo | Utilisation de derives d'indazolecarboxamides pour la preparation d'un medicament destine au traitement et a la prevention du paludisme |
| US7626021B2 (en) | 2004-07-27 | 2009-12-01 | Sgx Pharmaceuticals, Inc. | Fused ring heterocycle kinase modulators |
| CA2573573A1 (en) * | 2004-07-27 | 2006-02-09 | Sgx Pharmaceuticals, Inc. | Fused ring heterocycle kinase modulators |
| CA2644910C (en) * | 2006-03-31 | 2014-01-28 | Abbott Laboratories | Indazole compounds |
| DE102006030479A1 (de) | 2006-07-01 | 2008-03-20 | Merck Patent Gmbh | Indazolderivate |
| CA2668859A1 (en) | 2006-11-07 | 2008-05-15 | Proteologics Ltd. | Pyrimidine derivatives as posh and posh-ap inhibitors |
| MX2009013213A (es) * | 2007-06-08 | 2010-03-30 | Abbott Lab | Indazoles 5-sustituidos 5-heteroarilo como inhibidores de cinasa. |
| US8648069B2 (en) | 2007-06-08 | 2014-02-11 | Abbvie Inc. | 5-substituted indazoles as kinase inhibitors |
| WO2009061345A2 (en) * | 2007-11-07 | 2009-05-14 | Cornell Research Foundation, Inc. | Targeting cdk4 and cdk6 in cancer therapy |
| WO2009106980A2 (en) * | 2008-02-29 | 2009-09-03 | Pfizer Inc. | Indazole derivatives |
| JP5370957B2 (ja) | 2008-08-20 | 2013-12-18 | 学校法人日本大学 | アポトーシス抑制剤 |
| KR101061599B1 (ko) * | 2008-12-05 | 2011-09-02 | 한국과학기술연구원 | 비정상 세포 성장 질환의 치료를 위한 단백질 키나아제 저해제인 신규 인다졸 유도체, 이의 약학적으로 허용가능한염 및 이를 유효성분으로 함유하는 약학적 조성물 |
| CN102595899A (zh) * | 2009-08-10 | 2012-07-18 | 埃皮瑟瑞克斯有限公司 | 作为wnt/b-联蛋白信号传导途径抑制剂的吲唑及其治疗用途 |
| CN105037355B (zh) | 2009-08-10 | 2017-06-06 | 萨穆梅德有限公司 | Wnt信号传导途径的吲唑抑制剂及其治疗用途 |
| LT3001903T (lt) | 2009-12-21 | 2018-01-10 | Samumed, Llc | 1h-pirazolo[3,4-b]piridinai ir jų terapinis panaudojimas |
| WO2012064744A2 (en) | 2010-11-08 | 2012-05-18 | Lycera Corporation | Tetrahydroquinoline and related bicyclic compounds for inhibition of rorϒ activity and the treatment of disease |
| IN2014CN02646A (https=) * | 2011-09-14 | 2015-08-07 | Samumed Llc | |
| WO2013113762A1 (en) | 2012-01-31 | 2013-08-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and kits for predicting the risk of having a cutaneous melanoma in a subject |
| PH12017500997A1 (en) | 2012-04-04 | 2018-02-19 | Samumed Llc | Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof |
| US8889730B2 (en) | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
| NZ629282A (en) | 2012-05-04 | 2017-04-28 | Samumed Llc | 1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof |
| JP6242868B2 (ja) | 2012-05-08 | 2017-12-06 | リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ | ＲＯＲγのアゴニストとしての使用のためおよび疾患の処置のためのテトラヒドロ［１，８］ナフチリジンスルホンアミドおよび関連化合物 |
| WO2013169704A2 (en) | 2012-05-08 | 2013-11-14 | Merck Sharp & Dohme Corp. | TETRAHYDRONAPHTHYRIDINE AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE |
| RU2015106013A (ru) * | 2012-08-10 | 2016-10-10 | Ф. Хоффманн-Ля Рош Аг | Соединения пиразолкарбоксамида, композиции и способы применения |
| MX365640B (es) | 2012-12-21 | 2019-06-10 | Plexxikon Inc | Compuestos y metodos para la modulacion de quinasas y sus indicaciones. |
| EP2943198B1 (en) | 2013-01-08 | 2019-07-17 | Samumed, LLC | 3-(benzoimidazol-2-yl)-indazole inhibitors of the wnt signaling pathway and therapeutic uses thereof |
| US9315464B1 (en) * | 2013-01-31 | 2016-04-19 | Nant Holdings Ip, Llc | Small molecule inhibitors of influenza A RNA-dependent RNA polymerase |
| US9096549B2 (en) * | 2013-02-01 | 2015-08-04 | Acetylon Pharmaceuticals, Inc. | Selective HDAC3 inhibitors |
| EP2970200A1 (en) * | 2013-03-13 | 2016-01-20 | Abbvie Inc. | Pyridine cdk9 kinase inhibitors |
| EP2970177A1 (en) | 2013-03-15 | 2016-01-20 | Pfizer Inc. | Indole compounds that activate ampk |
| WO2015095788A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | 2-ACYLAMIDOMETHYL AND SULFONYLAMIDOMETHYL BENZOXAZINE CARBAMATES FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE |
| US9783511B2 (en) | 2013-12-20 | 2017-10-10 | Lycera Corporation | Carbamate benzoxazine propionic acids and acid derivatives for modulation of RORgamma activity and the treatment of disease |
| US9809561B2 (en) | 2013-12-20 | 2017-11-07 | Merck Sharp & Dohme Corp. | Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease |
| JP2017507950A (ja) | 2014-02-27 | 2017-03-23 | リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ | レチノイン酸受容体関連オーファン受容体ガンマのアゴニストを使用する養子細胞療法及び関連治療方法 |
| CN106535890A (zh) | 2014-03-20 | 2017-03-22 | 萨穆梅德有限公司 | 5‑取代的吲唑‑3‑羧酰胺及其制备和应用 |
| EP3140291A4 (en) | 2014-05-05 | 2018-01-10 | Lycera Corporation | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease |
| JP6523337B2 (ja) | 2014-05-05 | 2019-05-29 | リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ | ＲＯＲγのアゴニストとしての使用及び疾患治療のためのベンゼンスルホンアミド及び関連化合物 |
| KR101731624B1 (ko) * | 2014-07-01 | 2017-05-04 | 광주과학기술원 | 세포 리프로그래밍 유도용 조성물 |
| WO2016040181A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof |
| WO2016040184A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof |
| WO2016040180A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof |
| WO2016040190A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof |
| WO2016040188A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof |
| WO2016040185A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof |
| WO2016040182A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 2-(1h-indazol-3-yl)-1h-imidazo[4,5-c]pyridine and therapeutic uses thereof |
| WO2016040193A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof |
| CA2975997A1 (en) | 2015-02-11 | 2016-08-18 | Merck Sharp & Dohme Corp. | Substituted pyrazole compounds as rorgammat inhibitors and uses thereof |
| US10421751B2 (en) | 2015-05-05 | 2019-09-24 | Lycera Corporation | Dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease |
| AU2016276947A1 (en) | 2015-06-11 | 2017-12-14 | Lycera Corporation | Aryl dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORy and the treatment of disease |
| WO2016200339A1 (en) | 2015-06-12 | 2016-12-15 | National University Of Singapore | Selective anti-cancer compounds |
| GB201511382D0 (en) | 2015-06-29 | 2015-08-12 | Imp Innovations Ltd | Novel compounds and their use in therapy |
| WO2017023984A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof |
| WO2017023989A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
| WO2017024004A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
| US10463651B2 (en) | 2015-08-03 | 2019-11-05 | Samumed, Llc | 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-indazoles and therapeutic uses thereof |
| US10350199B2 (en) | 2015-08-03 | 2019-07-16 | Samumed, Llc | 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof |
| WO2017023972A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
| WO2017023996A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof |
| WO2017023988A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
| US10226453B2 (en) | 2015-08-03 | 2019-03-12 | Samumed, Llc | 3-(1H-indol-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof |
| US10383861B2 (en) | 2015-08-03 | 2019-08-20 | Sammumed, LLC | 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof |
| WO2017024003A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc | 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
| US10329309B2 (en) | 2015-08-03 | 2019-06-25 | Samumed, Llc | 3-(3H-imidazo[4,5-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof |
| WO2017023980A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof |
| WO2017023986A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc | 3-(1h-indol-2-yl)-1h-indazoles and therapeutic uses thereof |
| US10166218B2 (en) | 2015-08-03 | 2019-01-01 | Samumed, Llc | 3-(1H-indol-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof |
| WO2017023987A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof |
| US10519169B2 (en) | 2015-08-03 | 2019-12-31 | Samumed, Llc | 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof |
| WO2017035405A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amino compounds for treatment of immune and inflammatory disorders |
| AR106018A1 (es) | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos |
| WO2017035409A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders |
| WO2017035401A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amide compounds for treatment of immune and inflammatory disorders |
| JP2018535958A (ja) | 2015-10-27 | 2018-12-06 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | ＲＯＲγＴ阻害薬としての置換インダゾール化合物及びその使用 |
| EP3368535B1 (en) | 2015-10-27 | 2020-12-02 | Merck Sharp & Dohme Corp. | Heteroaryl substituted benzoic acids as rorgammat inhibitors and uses thereof |
| US10344000B2 (en) | 2015-10-27 | 2019-07-09 | Merck Sharp & Dohme Corp. | Substituted bicyclic pyrazole compounds as RORgammaT inhibitors and uses thereof |
| MX380092B (es) | 2015-11-06 | 2025-03-11 | Samumed Llc | Tratamiento de la osteoartritis. |
| AR108325A1 (es) | 2016-04-27 | 2018-08-08 | Samumed Llc | Isoquinolin-3-il carboxamidas y preparación y uso de las mismas |
| MX390577B (es) | 2016-06-01 | 2025-03-20 | Samumed Llc | Proceso de preparación de n-(5-(3-(7-(3-fluorofenil)-3h-imidazo[4,5-c]piridin-2-il)-1h-indazol-5-il)piridin-3-il)-3-metilbutanamida. |
| JP2019535672A (ja) | 2016-10-21 | 2019-12-12 | サミュメッド リミテッド ライアビリティ カンパニー | インダゾール−３−カルボキサミドの使用方法およびｗｎｔ／β−カテニンシグナル伝達経路阻害剤としてのそれらの使用 |
| MA46696A (fr) | 2016-11-07 | 2019-09-11 | Samumed Llc | Formulations injectables à dose unique prêtes à l'emploi |
| CN110603252A (zh) | 2017-03-01 | 2019-12-20 | 艾其林医药公司 | 用于治疗医学障碍的芳基、杂芳基和杂环药物化合物 |
| WO2018160891A1 (en) | 2017-03-01 | 2018-09-07 | Achillion Pharmaceutical, Inc. | Pharmaceutical compounds for treatment of medical disorders |
| EP3755696B1 (en) * | 2018-02-23 | 2023-04-05 | BioSplice Therapeutics, Inc. | 5-heteroaryl substituted indazole-3-carboxamides and preparation and use thereof |
| WO2020051538A1 (en) | 2018-09-06 | 2020-03-12 | Achillion Pharmaceuticals, Inc. | Morphic forms of complement factor d inhibitors |
| JP7443375B2 (ja) | 2018-09-06 | 2024-03-05 | アキリオン ファーマシューティカルズ， インコーポレーテッド | 医学的障害の治療のための大環状化合物 |
| KR20210093855A (ko) | 2018-09-25 | 2021-07-28 | 아칠리온 파르마세우티칼스 인코포레이티드 | 보체 인자 d 억제제의 형태체 형태 |
| WO2020131974A1 (en) | 2018-12-17 | 2020-06-25 | Achillion Pharmaceuticals, Inc. | Targeted dosing for the treatment of complement mediated disorders |
| BR112021018456A2 (pt) | 2019-03-22 | 2021-11-23 | Achillion Pharmaceuticals Inc | Compostos farmacêuticos para o tratamento de distúrbios mediados por complemento |
| EP4079732A4 (en) * | 2019-12-16 | 2023-10-18 | Korea Research Institute of Chemical Technology | NEW INDAZOLE DERIVATIVE AND ITS USE |
| WO2021222442A1 (en) | 2020-04-29 | 2021-11-04 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
| CN114230565B (zh) * | 2020-09-09 | 2023-10-27 | 成都奥睿药业有限公司 | 5-取代吲哚3-酰胺衍生物及其制备方法和用途 |
| WO2022113003A1 (en) | 2020-11-27 | 2022-06-02 | Rhizen Pharmaceuticals Ag | Cdk inhibitors |
| WO2022149057A1 (en) | 2021-01-05 | 2022-07-14 | Rhizen Pharmaceuticals Ag | Cdk inhibitors |
| KR20240020735A (ko) | 2021-05-07 | 2024-02-15 | 카이메라 쎄라퓨틱스 인코포레이티드 | Cdk2 분해제 및 그 용도 |
| CN114605329B (zh) * | 2022-03-28 | 2024-01-26 | 河南中医药大学 | 取代的吲唑甲酰胺或取代的氮杂吲唑甲酰胺类flt3抑制剂及其用途 |
| WO2024052685A1 (en) | 2022-09-09 | 2024-03-14 | MyricX Pharma Limited | Cytotoxic imidazo[1,2-a]pyridine compounds and their use in therapy |
| WO2024073502A1 (en) * | 2022-09-28 | 2024-04-04 | Accutar Biotechnology Inc. | Heterocyclic compounds as e3 ligase inhibitors |
| CN116874432B (zh) * | 2023-07-28 | 2025-08-05 | 常州大学 | 用作β2-肾上腺素受体拮抗剂的苯并咪唑类衍生物 |
| WO2024109642A1 (zh) * | 2023-07-28 | 2024-05-30 | 常州大学 | 一种苯并氮杂环类化合物作为β2-肾上腺素受体别构调节剂的应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3457269A (en) * | 1967-02-24 | 1969-07-22 | Sterling Drug Inc | N-substituted phenyl and n-substituted phenylalkyl 3 - indazolecarboxamides and preparation thereof |
| EP0410509A1 (en) * | 1989-07-25 | 1991-01-30 | Duphar International Research B.V | New substituted 1H-indazole-3-carboxamides |
| AU4949293A (en) * | 1992-08-28 | 1994-03-29 | Ciba-Geigy Ag | Indazole derivatives |
| KR100423899B1 (ko) * | 2000-05-10 | 2004-03-24 | 주식회사 엘지생명과학 | 세포 증식 억제제로 유용한 1,1-디옥소이소티아졸리딘을갖는 인다졸 |
| US7429609B2 (en) * | 2002-05-31 | 2008-09-30 | Eisai R & D Management Co., Ltd. | Pyrazole compound and medicinal composition containing the same |
| GB0218625D0 (en) | 2002-08-10 | 2002-09-18 | Astex Technology Ltd | Pharmaceutical compounds |
| WO2004014922A1 (en) | 2002-08-10 | 2004-02-19 | Astex Technology Limited | 3-(carbonyl) 1h-indazole compounds as cyclin dependent kinases (cdk) inhibitors |
| CN101012193A (zh) * | 2003-01-02 | 2007-08-08 | 霍夫曼-拉罗奇有限公司 | 新cb 1受体反激动剂 |
-
2002
- 2002-10-02 FR FR0212188A patent/FR2845382A1/fr active Pending
-
2003
- 2003-09-30 AU AU2003299125A patent/AU2003299125A1/en not_active Abandoned
- 2003-09-30 JP JP2004540862A patent/JP4762543B2/ja not_active Expired - Fee Related
- 2003-09-30 WO PCT/FR2003/002862 patent/WO2004031158A1/fr not_active Ceased
- 2003-09-30 EP EP03798949A patent/EP1549620A1/fr not_active Withdrawn
- 2003-10-01 AR ARP030103581A patent/AR041459A1/es unknown
- 2003-10-01 TW TW092127213A patent/TWI331603B/zh not_active IP Right Cessation
-
2005
- 2005-04-01 US US11/096,375 patent/US7482342B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP4762543B2 (ja) | 2011-08-31 |
| US7482342B2 (en) | 2009-01-27 |
| TWI331603B (en) | 2010-10-11 |
| FR2845382A1 (fr) | 2004-04-09 |
| AU2003299125A1 (en) | 2004-04-23 |
| EP1549620A1 (fr) | 2005-07-06 |
| US20060004000A1 (en) | 2006-01-05 |
| WO2004031158A1 (fr) | 2004-04-15 |
| JP2006504711A (ja) | 2006-02-09 |
| TW200418805A (en) | 2004-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR041459A1 (es) | Derivados de indazolcarboxamidas su preparacion y su utilizacion en terapeutica | |
| EA200970149A1 (ru) | Производные n-(аминогетероарил)-1h-индол-2-карбоксамидов, их получение и их применение в терапии | |
| HRP20080549T3 (en) | 1,3,5-trisubstituted 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity | |
| TW200614983A (en) | 5-substituted-2-phenylamino benzamides as MEK inhibitors | |
| MY146377A (en) | Use of indazolecarboxamide derivatives for preparing a medicinal product intended for the treatment and prevention of malaria. | |
| JP2016522172A5 (https=) | ||
| AR057244A1 (es) | Compuestos agonistas,antagonistas o agonistas inversos de receptores cb2,composiciones farmaceuticas que los contienen, metodos de preparacion y usos para tratar enfermedades inflamatorias y/o autoinmunes. | |
| ATE453639T1 (de) | Phenylsubstituierte pyrimidinverbindungen zur verwendung als kinasehemmer | |
| ATE508747T1 (de) | C-kit kinase-hemmer | |
| EA200600509A1 (ru) | Соединения пиримидотиофена | |
| AR037477A1 (es) | 2-tio-3, 5-diciano-4-fenil-6-aminopiridinas substituidas y su uso | |
| AR051839A1 (es) | Metodo para preparar n-fenilpirazol -1- carboxamidas | |
| WO2007016392A3 (en) | Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors | |
| EA200700117A1 (ru) | N-замещенные пиперидины и их применение в качестве фармацевтических препаратов | |
| BRPI0821653B8 (pt) | composto de piridina substituída com anel heterocíclico e grupo fosfonoximetila ou um sal do mesmo, composição farmacêutica compreendendo-os e uso dos mesmos para tratar uma doença fungíca | |
| ATE536349T1 (de) | In der 2-stellung durch phenyl substituierte 1h- benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren | |
| DK1755606T4 (da) | Quinazolinonderivater, der er anvendelige som vanilloid-antagonister | |
| SE0403171D0 (sv) | New compounds | |
| AR033879A1 (es) | Compuesto sulfonamida, composicion farmaceutica que lo comprende, su uso para preparar dicha composicion y procedimiento para la obtencion de dicho compuesto | |
| WO2007119001A3 (fr) | Derives d 'aminomethyl pyridine, leur preparation et leur application en therapeutique | |
| HRP20090474T1 (hr) | Postupak i intermedijeri za sintezu kaspofungina | |
| RU2368608C2 (ru) | Производные пиперидина в качестве модуляторов хемокинового рецептора ccr5 | |
| EA200600100A1 (ru) | Производные никотинамида, полезные в качестве ингибиторов pde4 | |
| WO2006092507A8 (fr) | Derives de 1 ,2,4-triazines, leur preparation et leur application en therapeutique humaine | |
| DOP2006000225A (es) | Derivados de 6-heteroarilpiridoindolona, su preparación y su aplicación en terapéutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |